Anti-TNF | ||||||
---|---|---|---|---|---|---|
All (n = 4736) | ETA (n = 934) | INF (n = 561) | ADA (n = 1,218) | GOL (n = 858) | TOC (n = 1165) | |
Duration of follow-up (days), median (IQR) | 569 (230–1075) | 640 (256–1225) | 642 (222–1174) | 510 (216–931) | 475 (204–984) | 612 (281–1061) |
Person-years | 8650.8 | 1879.7 | 1087.1 | 2050.9 | 1447.5 | 2185.6 |
Case of TB, n | 48 | 7 | 13 | 12 | 6 | 10 |
Rate/100,000 person-years (95% CI) | 554.9 (412.3–727.0) | 372.4 (160.0–720.1) | 1195.8 (657.8–1968.5) | 585.1 (313.3–981.2) | 414.5 (164.7–839.9) | 457.5 (229.3–802.4) |
Adjusted IRRa | 1.00 (ref) | 3.06 (1.22–7.69) | 1.69 (0.66–4.33) | 1.22 (0.41–3.67) | 1.25 (0.47–3.31) |